DK2393485T3 - Tolagstabletter, der omfatter elvitegravir, cobicistat, emtricitabin og tenofovir - Google Patents
Tolagstabletter, der omfatter elvitegravir, cobicistat, emtricitabin og tenofovir Download PDFInfo
- Publication number
- DK2393485T3 DK2393485T3 DK10703766.5T DK10703766T DK2393485T3 DK 2393485 T3 DK2393485 T3 DK 2393485T3 DK 10703766 T DK10703766 T DK 10703766T DK 2393485 T3 DK2393485 T3 DK 2393485T3
- Authority
- DK
- Denmark
- Prior art keywords
- formula
- compound
- tablet
- layer
- iii
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (20)
- TOLAGSTABLETTER, DER OMFATTER ELVITEGRAVIR, COBICISTAT, EMTRICIT AB IN OG TENOFOVIR1. Tablet, der omfatter et første lag og et andet lag, hvor; a) det første lag omfatter: en forbindelse med formlen I:og en forbindelse med formlen II:og eventuelt en farmaceutisk acceptabel bærer; og b) det andet lag omfatter: en forbindelse med formlen III: oget salt med formlen IV:IV > og eventuelt en farmaceutisk acceptabel bærer.
- 2. Tablet ifølge krav 1, hvor det første lag er i kontakt med det andet lag.
- 3. Tablet ifølge et hvilket som helst af kravene 1-2, hvor vægtforholdet mellem forbindelsen med formlen I og forbindelsen med formlen II er 1,0 ± 0,5.
- 4. Tablet ifølge et hvilket som helst af kravene 1-3, hvor det første lag endvidere omfatter et antal af siliciumdioxidpartikler.
- 5. Tablet ifølge et hvilket som helst af kravene 1-3, hvor forbindelsen med formlen II er forbundet med siliciumdioxidpartikler.
- 6. Tablet ifølge et hvilket som helst af kravene 1-5, der omfatter 150 mg ± 10 % af forbindelsen med formlen I; 150 mg ± 10 % af forbindelsen med formlen II; 200 mg ± 10 % af forbindelsen med formlen III; og 300 mg ± 10 % af forbindelsen med formlen IV.
- 7. Tablet ifølge krav 6, der omfatter 150 mg ± 5 % af forbindelsen med formlen I.
- 8. Tablet ifølge krav 6, der omfatter 150 mg ± 2 % af forbindelsen med formlen I.
- 9. Tablet ifølge et hvilket som helst af kravene 6-8, der omfatter 150 mg ± 5 % af forbindelsen med formlen II.
- 10. Tablet ifølge et hvilket som helst af kravene 6-8, der omfatter 150 mg ± 2 % af forbindelsen med formlen II.
- 11. Tablet ifølge et hvilket som helst af kravene 6-10, der omfatter 200 mg ± 5 % af forbindelsen med formlen III.
- 12. Tablet ifølge et hvilket som helst af kravene 6-10, der omfatter 200 mg ± 2 % af forbindelsen med formlen III.
- 13. Tablet ifølge et hvilket som helst af kravene 6-12, der omfatter 300 mg ± 5 % af saltet med formlen IV.
- 14. Tablet ifølge et hvilket som helst af kravene 6-12, der omfatter 300 mg ± 2 % af saltet med formlen IV.
- 15. Tablet ifølge et hvilket som helst af kravene 1-14, der endvidere omfatter en farmaceutisk acceptabel bærer.
- 16. Tablet ifølge et hvilket som helst af kravene 1-15, der er formuleret i en doseringsenhedsform.
- 17. Tabiet ifølge et hvilket som helst af kravene 1-16, der er formuleret til dosering én gang dagligt.
- 18. Fremgangsmåde til fremstilling af en tablet som beskrevet i krav 1, der omfatter: komprimering af en sammensætning, der omfatter forbindelsen med formlen I, og forbindelsen med formlen II til tilvejebringelse af et første komprimeret lag; tilføjelse af forbindelsen med formlen III og saltet med formlen IV til det første pressede lag; og komprimering for tilvejebringelse af tabletten.
- 19. Tablet som beskrevet i krav 1, der består af følgende:
- 20. Tablet fremstillet som beskrevet i krav 18.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15065509P | 2009-02-06 | 2009-02-06 | |
| US15065209P | 2009-02-06 | 2009-02-06 | |
| PCT/US2010/023226 WO2010091197A2 (en) | 2009-02-06 | 2010-02-04 | Tablets for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2393485T3 true DK2393485T3 (da) | 2015-10-26 |
Family
ID=41722740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10703766.5T DK2393485T3 (da) | 2009-02-06 | 2010-02-04 | Tolagstabletter, der omfatter elvitegravir, cobicistat, emtricitabin og tenofovir |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US20100285122A1 (da) |
| EP (1) | EP2393485B1 (da) |
| JP (2) | JP5611242B2 (da) |
| KR (2) | KR101645759B1 (da) |
| CN (1) | CN102307573B (da) |
| AP (1) | AP3250A (da) |
| AR (1) | AR075369A1 (da) |
| AU (1) | AU2010210598B2 (da) |
| BR (1) | BRPI1008664A2 (da) |
| CA (1) | CA2750521A1 (da) |
| CL (1) | CL2011001885A1 (da) |
| CY (1) | CY1116852T1 (da) |
| DK (1) | DK2393485T3 (da) |
| EA (2) | EA030123B1 (da) |
| EC (1) | ECSP11011307A (da) |
| ES (1) | ES2548886T3 (da) |
| HK (1) | HK1164737A1 (da) |
| HR (1) | HRP20151009T1 (da) |
| HU (1) | HUE025822T2 (da) |
| IL (1) | IL214227A (da) |
| MX (1) | MX2011008289A (da) |
| NZ (1) | NZ594214A (da) |
| PE (1) | PE20110994A1 (da) |
| PL (1) | PL2393485T3 (da) |
| PT (1) | PT2393485E (da) |
| SG (3) | SG173544A1 (da) |
| SI (1) | SI2393485T1 (da) |
| SM (1) | SMT201500266B (da) |
| TW (1) | TWI444367B (da) |
| UY (1) | UY32424A (da) |
| WO (1) | WO2010091197A2 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA020489B1 (ru) | 2006-07-07 | 2014-11-28 | Джилид Сайэнс, Инк. | Модуляторы фармакокинетических свойств лекарственных средств |
| SG183059A1 (en) * | 2007-02-23 | 2012-08-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
| PL2296633T3 (pl) | 2008-05-02 | 2016-03-31 | Gilead Sciences Inc | Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego |
| TWI556840B (zh) | 2010-11-19 | 2016-11-11 | 吉李德科學股份有限公司 | 治療用組成物 |
| WO2012072580A1 (en) * | 2010-11-29 | 2012-06-07 | Formac Pharmaceuticals N.V. | Compressed formulations of ordered mesoporous silicas |
| SI2729130T1 (en) * | 2011-07-07 | 2018-03-30 | Janssen Sciences Ireland Uc | Combined formulations of darunavir |
| RS55353B2 (sr) | 2011-08-16 | 2023-11-30 | Gilead Sciences Inc | Tenofovir alafenamid hemifumarat |
| WO2013115916A1 (en) * | 2012-02-03 | 2013-08-08 | Gilead Sciences, Inc. | Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections |
| EA026138B1 (ru) * | 2012-02-03 | 2017-03-31 | Джилид Сайэнс, Инк. | Комбинированная терапия, включающая тенофовир алафенамида гемифумарат и кобицистат, для применения для лечения вирусных инфекций |
| US20150045366A1 (en) * | 2012-03-01 | 2015-02-12 | Gilead Sciences, Inc. | Spray dried formulations |
| CN103830192A (zh) * | 2012-11-27 | 2014-06-04 | 安徽贝克生物制药有限公司 | 一种可粉末直接压片的富马酸替诺福韦二吡呋酯片剂及制备方法 |
| DK3067358T3 (da) | 2012-12-21 | 2019-11-04 | Gilead Sciences Inc | Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse |
| PT3607939T (pt) | 2015-06-30 | 2022-09-12 | Gilead Sciences Inc | Formulações farmacêuticas compreendendo tenofovir e emtricitabina |
| CN113546052A (zh) | 2015-11-09 | 2021-10-26 | 吉利德科学公司 | 治疗人免疫缺陷病毒的治疗组合物 |
| ES2806604T3 (es) | 2016-02-02 | 2021-02-18 | Sandoz Ag | Formas cristalinas de monofumarato de tenofovir alafenamida |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA923640B (en) | 1991-05-21 | 1993-02-24 | Iaf Biochem Int | Processes for the diastereoselective synthesis of nucleosides |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| DE10153078A1 (de) * | 2001-10-30 | 2003-05-22 | Degussa | Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen |
| CN100375742C (zh) * | 2002-11-20 | 2008-03-19 | 日本烟草产业株式会社 | 4-氧代喹啉化合物及其用途 |
| SK2662004A3 (sk) | 2002-11-20 | 2005-06-02 | Japan Tobacco, Inc. | Zlúčenina s obsahom 4-oxochinolínu a jej použitie ako inhibítora integráz |
| JP3567162B1 (ja) * | 2002-11-20 | 2004-09-22 | 日本たばこ産業株式会社 | ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用 |
| DE602004014470D1 (de) | 2003-01-14 | 2008-07-31 | Gilead Sciences Inc | Zusammensetzungen und verfahren zur antiviralen kombinationstherapie |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| TWI471145B (zh) * | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| KR20080091767A (ko) * | 2005-12-14 | 2008-10-14 | 씨아이피엘에이 엘티디. | (테노포비어 및 라미뷰딘과 같은) 뉴클레오티드 역전사효소억제제 및 뉴클레오시드 역전사효소 억제제를 투여 단위의상이한 부분에 포함하는 약제학적 조합물 |
| EA020489B1 (ru) * | 2006-07-07 | 2014-11-28 | Джилид Сайэнс, Инк. | Модуляторы фармакокинетических свойств лекарственных средств |
| SG183059A1 (en) * | 2007-02-23 | 2012-08-30 | Gilead Sciences Inc | Modulators of pharmacokinetic properties of therapeutics |
-
2010
- 2010-02-04 MX MX2011008289A patent/MX2011008289A/es active IP Right Grant
- 2010-02-04 EA EA201491658A patent/EA030123B1/ru not_active IP Right Cessation
- 2010-02-04 PL PL10703766T patent/PL2393485T3/pl unknown
- 2010-02-04 HU HUE10703766A patent/HUE025822T2/en unknown
- 2010-02-04 SI SI201031019T patent/SI2393485T1/sl unknown
- 2010-02-04 DK DK10703766.5T patent/DK2393485T3/da active
- 2010-02-04 US US12/700,608 patent/US20100285122A1/en not_active Abandoned
- 2010-02-04 JP JP2011549268A patent/JP5611242B2/ja not_active Expired - Fee Related
- 2010-02-04 PT PT107037665T patent/PT2393485E/pt unknown
- 2010-02-04 ES ES10703766.5T patent/ES2548886T3/es active Active
- 2010-02-04 BR BRPI1008664A patent/BRPI1008664A2/pt not_active Application Discontinuation
- 2010-02-04 EA EA201190125A patent/EA021313B1/ru not_active IP Right Cessation
- 2010-02-04 WO PCT/US2010/023226 patent/WO2010091197A2/en active Application Filing
- 2010-02-04 SG SG2011056306A patent/SG173544A1/en unknown
- 2010-02-04 EP EP10703766.5A patent/EP2393485B1/en not_active Revoked
- 2010-02-04 SG SG2014007744A patent/SG2014007744A/en unknown
- 2010-02-04 CA CA2750521A patent/CA2750521A1/en not_active Abandoned
- 2010-02-04 CN CN2010800066460A patent/CN102307573B/zh not_active Expired - Fee Related
- 2010-02-04 AP AP2011005857A patent/AP3250A/xx active
- 2010-02-04 SG SG10201706215UA patent/SG10201706215UA/en unknown
- 2010-02-04 AU AU2010210598A patent/AU2010210598B2/en not_active Ceased
- 2010-02-04 NZ NZ594214A patent/NZ594214A/xx not_active IP Right Cessation
- 2010-02-04 PE PE2011001449A patent/PE20110994A1/es active IP Right Grant
- 2010-02-04 KR KR1020117020652A patent/KR101645759B1/ko active Application Filing
- 2010-02-04 KR KR1020167020504A patent/KR101738325B1/ko not_active Application Discontinuation
- 2010-02-05 AR ARP100100328A patent/AR075369A1/es unknown
- 2010-02-06 TW TW099103651A patent/TWI444367B/zh not_active IP Right Cessation
- 2010-02-08 UY UY0001032424A patent/UY32424A/es not_active Application Discontinuation
-
2011
- 2011-07-21 IL IL214227A patent/IL214227A/en not_active IP Right Cessation
- 2011-08-05 CL CL2011001885A patent/CL2011001885A1/es unknown
- 2011-09-06 EC EC2011011307A patent/ECSP11011307A/es unknown
-
2012
- 2012-06-12 HK HK12105696.2A patent/HK1164737A1/xx not_active IP Right Cessation
-
2014
- 2014-09-02 JP JP2014178005A patent/JP5911927B2/ja active Active
-
2015
- 2015-02-06 US US14/616,563 patent/US20150150810A1/en not_active Abandoned
- 2015-09-24 HR HRP20151009TT patent/HRP20151009T1/hr unknown
- 2015-10-26 CY CY20151100953T patent/CY1116852T1/el unknown
- 2015-10-28 SM SM201500266T patent/SMT201500266B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2393485T3 (da) | Tolagstabletter, der omfatter elvitegravir, cobicistat, emtricitabin og tenofovir | |
| EP1753406B2 (en) | Coated tablet formulation and method | |
| EP2136793B1 (en) | Tablet formulations containing 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom | |
| KR101923103B1 (ko) | 릴피비린 hcl 및 테노포비어 디소프록실 푸마레이트를 포함하는 치료 조성물 | |
| CN102858324A (zh) | 包含阿片样激动剂和拮抗剂的双层药物制剂 | |
| CN104363896A (zh) | 恩替卡韦的药物组合物及制造方法 | |
| EP2804588B1 (en) | Method for producing cinacalcet compositions for direct tableting | |
| JP2019526591A (ja) | ロスバスタチン及びエゼチミブを含む医薬組成物並びにその調製方法 | |
| AU2015200637C1 (en) | Tablets for combination therapy | |
| EP3511001B1 (en) | Pirfenidone-containing tablet and capsule formulation | |
| JP2022151564A (ja) | 薬効成分としてビルダグリプチンおよびメトホルミンを含む錠剤 |